SUMMARY Agranulocytosis and aplastic anaemia associated with sulphasalazine are well recognised, but pancytopenia caused by acute megaloblastic arrest of haemopoeiesis while taking sulphasalazine has not previously been described. We report three patients who, after taking sulphasalazine for over two years, suddenly developed severe pancytopenia with gross megaloblastic changes in the marrow. In two patients there was a good response to high dose oral folic acid but the third required folinic acid. The mechanism appears to be acute folate deficiency, and the requirement for folinic acid in one case suggests that the known inhibition of folate metabolism by sulphasalazine also contributes. The syndrome appears to be associated with high dosage and slow acetylator status. The drug has been successfully restarted at reduced dosage with folate supplements in two patients both of whom were slow acetylators. In the third case, whose acetylator status is not known, progression of her disease led to colectomy.
Sulphasalazine has been used in the treatment of inflammatory bowel disease for many years. Although the therapeutic metabolite appears to be 5'amino salicylic acid which is minimally absorbed from the colon, the sulphapyridine moiety is responsible for the major haematological side effects: these include aplastic anaemia and haemolysis which are well documented and very rarely megaloblastic anaemia caused by folate deficiency. [1] [2] [3] This has been variously attributed to folate depletion secondary to either active inflammatory bowel disease or to chronic haemolysis induced by the drug. In vitro work has also shown a more specific antifolate action of sulphasalazine47 and this may be the cause of the reduced red cell folate levels found in patients on long term maintenance with the drug.8 Individuals who are slow acetylators may achieve high plasma sulphapyridine concentrations even on normal dosage. We report three patients, two of whom were slow acetylators, who had received sulphasalazine for some years and who presented acutely ill with pancytopenia apparently due to severe folate deficiency. Thus, while pancytopenia developing in a patient on sulphasalazine is usually caused by aplastic anaemia or by bone marrow necrosis16 it may be caused by acute folate deficiency which can be diagnosed by bone marrow examination and estimation of red cell folate levels. We are aware of one previous death from acute folate deficiency due to sulphasalazine, (personal communication JCP Weber) but the incidence may be more common. As 22 of the 27 deaths attributed to sulphasalazine and reported to the committee on Safety of Medicines between 1964-84, were caused by aplastic anaemia, agranulocytosis or undefined pancytopenia, accurate diagnosis is essential. '7 Each of our three cases had been on sulphasalazine for some years and therefore were likely to have had low folate stores, particularly case 3 who may also have had chronic haemolysis. All cases had normal diets and Schilling tests, carried out after initial treatment with both folate and vitamin B,2, showed normal absorption with and without intrin-sic factor. In the first and third cases folate levels were low at diagnosis but unfortunately because of the microbiological methods in use at the time no levels for vitamin B12 or folate are available for case 2. There is no evidence to suspect that the megaloblastic anaemia was because of vitamin B12 deficiency as her haemoglobin and MCV were normal six months earlier and the rapidity of onset and severity of her symptoms would be unusual in a pure vitamin B12 deficient state. In spite of being given ACTH to treat her Crohn's disease this was still active when the Schilling test was done and this could not have contributed to vitamin B12 malabsorption. Clinically and morphologically she was identical to case 1 and other reported cases of acute folate deficiency. The low serum vitamin B12 level in case 3 probably reflects the recognised reduction in vitamin B12 levels that can occur secondary to severe folate deficiency18 19 as again there is no reasonable explanation for why he should have become deficient in vitamin B12 as a primary cause of his megaloblastic state. All three became acutely megaloblastic during either an intercurrent illness or relapse of their bowel condition. The time between the start of treatment with sulphasalazine and the onset of probable acute folate deficiency is suggestive of a dose dependent effect related to plasma levels of sulphapyridine rather than a hypersensitivity reaction, and indeed two of the three patients are slow acetylators. The response of cases 2 and 3 to high doses of oral folic acid would be expected if the drug were competitively inhibiting folate absorption and metabolism. In case 1, this form of therapy was inadequate, but the dramatic haematological response to folinic acid, which bypasses the folate metabolising enzymes known to be inhibited by sulphasalazine, suggests that a metabolic block was present. A competitive action of the drug is also suggested by the fact that cases 1 and 3 have safely been restarted on the drug with folate supplements and are now haematologically normal.
The first case had a very high transcobalamin II level but further investigation of this has shown it to be capable of normal transfer of vitamin B12 into transformed lymphocytes and reticulocytes. It is unlikely therefore that the very low red cell folate was secondary to reduced cellular vitamin B12 which is required for normal entry of folic acid into red cells.
While acute folate deficiency is an uncommon unwanted effect of sulphasalazine it can be a life threatening event in previously well controlled patients and may be precipitated by a mild intercurrent illness or an exacerbation of inflammatory bowel disease resulting in increased folate demands. Acute folate deficiency results when the tissues are already folate depleted through the antifolate actions of maintenance sulphasalazine. This may present as a sudden drop in haemoglobin with a pancytopenia but only minimal macrocytosis in the peripheral blood. Large doses of oral folic acid may be sufficient treatment but intravenous folinic acid may be necessary as a rapid means of overcoming the antifolate actions of sulphasalazine. This effect of sulphasalazine does appear to be a dose related phenomenon and should not be considered a contraindication to later reintroducing sulphasalazine in a reduced dosage. 
